Results 211 to 220 of about 472,049 (341)

Immunoinformatics-driven design of a multi-epitope vaccine targeting neonatal rotavirus with focus on outer capsid proteins VP4 and VP7 and non structural proteins NSP2 and NSP5 [PDF]

Arijit Das Sharma, Jorge Samuel Leon Magdaleno, Himanshu Singh, Andrés Felipe Cuspoca Orduz, Luigi Cavallo, Mohit Chawla   +5 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial. [PDF]

EClinicalMedicine
Brglez V, Teisseyre M, Zorzi K, Fernandez C, Cremoni M, Crepin T, Lanot A, Gueutin V, Novel-Catin E, Rigothier C, Pelletier C, Knebelmann B, Chauveau D, Audard V, Halimi JM, Verhelst D, Cambiaggio S, Legueult K, Bailly L, Lambeau G, Esnault V, Moranne O, Seitz-Polski B.   +22 more
europepmc   +1 more source

Design and Evaluation of Optimized Artificial HIV-1 Poly-T Cell-Epitope Immunogens

, 2015
Alena Reguzova, Денис Антонец, Л. И. Карпенко, A. A. Ilyichev, Rinat А. Maksyutov, Sergei I. Bazhan   +5 more
openalex   +2 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Corrigendum: Structural Influence on the Dominance of Virus-Specific CD4 T Cell Epitopes in Zika Virus Infection

Frontiers in Immunology, 2018
Maximilian Koblischke, Karin Stiasny, Stephan W. Aberle, Stefan Malafa, Georgios Tsouchnikas, Julia Schwaiger, Michael Kundi, Franz X. Heinz, Judith H. Aberle   +8 more
doaj   +1 more source

In silico design of a multi-epitope vaccine against the triple negative breast cancer. [PDF]

Sci Rep
Zahraei M, Roohparvar Basmenj E, Behrouzi G, Heidari Keshel S, Alem M.   +4 more
europepmc   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

The Decade of Porcine Circovirus Type 2 (PCV2) in Thailand: Phylodynamic and Molecular Epidemiology. [PDF]

Transbound Emerg Dis
Sritrakul T, Thanantong N, Boonsoongnern A, Jirawattanapong P, Woonwong Y, Soda N, Kaminsonsakul T, Klinsawat W, Lekcharoensuk P, Sukmak M.   +9 more
europepmc   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source